Navigation Links
Immune Design Appoints Stephen R. Brady Chief Business Officer
Date:9/26/2013

SEATTLE and SAN FRANCISCO, Sept. 26, 2013 /PRNewswire/ -- Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced the appointment of Stephen R. Brady as its Chief Business Officer.

(Logo: http://photos.prnewswire.com/prnh/20130926/SF87058LOGO)

Mr. Brady brings extensive experience to lead Immune Design's business functions, including strategic planning and corporate development activities. His appointment in this new position is a reflection of the Company's maturing immune-based therapeutic programs and productive platform technology.

"Steve is an experienced and accomplished executive with a successful track record of executing successful business development and corporate strategies," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune Design. "He is a key addition to our expanded management team and will play an important role in advancing and expanding our strategic activities."

"Immune Design's combination of both novel antigen-specific and innate immunity approaches is an exciting potential advancement in the area of cancer immunotherapy," said Mr. Brady.  "I look forward to working with the team to move existing programs forward and further expand the reach of the company's platform technology in oncology, infectious disease and allergies."

Most recently, Mr. Brady served as Chief Business Officer for 3-V Biosciences, Inc., where he led business and operations activities, including finance, legal, corporate communications and strategic portfolio planning. Previously, he served as Vice President of Corporate Development for Proteolix, Inc., where he was primarily responsible for corporate development and legal affairs, including the sale of the Company to Onyx Pharmaceuticals for $851M in 2009. Prior to his tenure with Proteolix, Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served primarily in business development and legal capacities.  Mr. Brady was also a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co, LLC., and an associate in the New York and San Francisco offices of Morrison & Foerster LLP.  Mr. Brady received a B.A. in English from the University of Oregon and a LL.M. from New York University School of Law.

The Immune Design Approach

Immune Design's immunotherapy approach is designed to both activate and deliver tumor antigens to dendritic cells in vivo to trigger specific, broad, and effective anti-tumor immune responses. The company's pipeline includes LV305 and G305 product candidates generated from two distinct technologies. Immune Design's proprietary lentiviral vector platform selectively targets dermal DCs in vivo to induce a powerful and durable pool of tumor specific cytotoxic T lymphocytes (CTLs). The company's synthetic TLR4 agonist, GLA, is a powerful inducer of innate immunity on its own and also triggers a potent and specific cellular and humoral anti-tumor immune response when it is combined with a tumor antigen. The LV305 and G305 product candidates will be individually tested in parallel in oncology indications and, upon demonstration of safety and immunogenicity, will then be tested in combination. These technologies may be applied in other allergy and infectious disease settings as well.

About Immune Design
Immune Design is a privately held, clinical stage biotechnology company based in Seattle, WA.  Immune Design brings together some of the world's leaders in the field of molecular immunology to develop a synergistic platform of next-generation therapeutic vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. The company employs leading-edge technologies that target dendritic cells for more precise activation of the immune response. These include a novel lentiviral vector engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo and a TLR4 agonist that activates dendritic cells by up-regulating key molecules for efficient antigen presentation and produces Th1 cytokines to enhance the immune response. For more information, visit www.immunedesign.com.


'/>"/>
SOURCE Immune Design
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
2. NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer
3. Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
4. Researchers identify signals that direct the immune system to reject a transplanted organ
5. arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders
6. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
7. Penn researchers develop protein passport that help nanoparticles get past immune system
8. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases
9. Small peptide ameliorates autoimmune skin blistering disease in mice
10. New Research Helps Explain Weakened Immune Response in Elderly
11. Autoimmune disease retraining white blood cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... 2016 , ... Cambridge Semantics, the leading provider of Smart Data ... has been named to The Silicon Review’s “20 Fastest Growing Big Data Companies of ... serves the needs of end users facing some of the most complex data challenges ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Pittcon Organizing Committee is pleased ... has been a volunteer member of Committee since 1987. Since then, he has served ... and treasurer and was chairman for both the program and exposition committees. In his ...
(Date:4/27/2016)... 27, 2016 NanoStruck Technologies ... NSKQB) ( Frankfurt : 8NSK) gibt ... vom 13. August 2015 die Genehmigung von der ... zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, ... Davon wurden 157.900.000 Einheiten mit dem ersten Teil ...
(Date:4/27/2016)... ... 27, 2016 , ... The Board of Directors of Biohaven ... Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. ... responsible for the commercialization of multiple orphan drug indications. Mr. Tilton has ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):